Home Biosimilar Antibodies Protein Tyrosine Kinase HER2 Margetuximab (Anti-ERBB2 / HER2 / CD340)
For research use only. Not for use in humans.

Margetuximab (Anti-ERBB2 / HER2 / CD340)

Synonyms: erbB-2， CD340

Margetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD.

Margetuximab (Anti-ERBB2 / HER2 / CD340)

Quality Control

Batch: A289901 Purity: 99% Protein concentration: 7.96mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation HER2 Others
Canertinib (CI-1033) 51 EGFR
CP-724714 109
Sapitinib (AZD8931) 50 ErbB3,EGFR
CUDC-101 23 EGFR,HDAC,HDAC1
Mubritinib (TAK 165) 41
AEE788 (NVP-AEE788) 16 EGFR,c-Abl,FLT1
AC480 (BMS-599626) 12 HER1,HER4
TAK-285 5 EGFR/HER1,HER4,MEK1
Tyrphostin AG 879 3 Trk
Tuxobertinib (BDTX-189) 3 EGFR,RIPK2,BLK
Epertinib hydrochloride 1 EGFR,HER4
TAS0728 1
Tyrphostin AG-528 0 EGFR
SU5204 1 VEGFR-2
Pyrotinib dimaleate 6 EGFR
Poziotinib (NOV120101, HM781-36B) 37 HER1,HER4
HER2-Inhibitor-1 1
Zongertinib (BI 1810631) 1 EGFR-Ex20ins
Nordihydroguaiaretic acid (NDGA) 2 p300,IGF-1R,lipoxygenase
EGCG ((-)-Epigallocatechin Gallate) 42 FASN,EGFR,DNMT
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Margetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD.
References

Product Details

CAS No. 1350624-75-7
Molecular Weight 146.1
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06365008 NOT_YET_RECRUITING Drug: Sintilimab+irinotecan+leucovorin folinate+fluorouracil Unresectable/Metastatic Gastric Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2026-06 PHASE2
NCT07661927 RECRUITING Drug: Removing Endocrine Therapy Breast Cancer (Early Breast Cancer) UNICANCER 2026-07-06 PHASE2
NCT07717450 NOT_YET_RECRUITING Metastatic Invasive Breast Cancer UNICANCER 2026-09-25 PHASE3
NCT07101159 NOT_YET_RECRUITING Drug: Dalpiciclib|Drug: Endocrine Therapy (Tamoxifen, Anastr Early Breast Cancer; Adjuvant Therapy; Hormone Receptor Positive / HER2-negative Breast Cancer Fujian Cancer Hospital 2025-09 PHASE2
NCT07288359 RECRUITING Drug: GVV858|Drug: Fulvestrant|Drug: Letrozole Advanced HR+/HER2- Breast Cancer; Advanced CCNE1-amplified Solid Tumors; Metastatic Castration-resistant Prostate Cancer Novartis Pharmaceuticals 2025-12-29 PHASE1; PHASE2
NCT07371910 ACTIVE_NOT_RECRUITING Drug: Chemotherapy/ADC Regimen|Drug: Fluorizoparib|Drug: Apa Metastatic Breast Cancer; HRD-Positive/HER2-Negative Advanced Breast Cancer Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 2024-06-12 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-06-18)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.